Skip to main content
Article
Abstract 4350: Low frequencies of SF3B1 mutations indicate SF3B1 inhibitor as a novel moleculartargeted drug for colorectal cancer.
Cancer Research (2013)
  • Tomoki Yamano, Hyogo College of Medicine
  • Hidenori Nakajima, 2Drug Discovery Research, Fermentation Research Laboratories, Tsukuba, Japan;
  • Satoshi Tsuda, Hyogo College of Medicine
  • Shuji Kubo, Hyogo College of Medicine
  • Mie Hamanaka, Hyogo College of Medicine
  • Masayoshi Kobayashi, Hyogo College of Medicine
  • Daisuke Yamagishi, Hyogo College of Medicine
  • Takashi Kuno, Hyogo College of Medicine
  • Kiyoshi Tsukamoto, Hyogo College of Medicine
  • Astuko Tamamoto, Hyogo College of Medicine
  • Masafumi Noda, Hyogo College of Medicine
  • Nagahide Matsubara, Hyogo College of Medicine
  • Dave Sb Hoon
  • Naohiro Tomita, Hyogo College of Medicine
Publication Date
April 15, 2013
DOI
10.1158/1538-7445.AM2013-4350
Citation Information
Tomoki Yamano, Hidenori Nakajima, Satoshi Tsuda, Shuji Kubo, et al.. "Abstract 4350: Low frequencies of SF3B1 mutations indicate SF3B1 inhibitor as a novel moleculartargeted drug for colorectal cancer." Cancer Research Vol. 73 (2013) p. 4350 - 4350
Available at: http://works.bepress.com/dave-hoon/119/